Alberto Jaramillo-Jimenez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alberto Jaramillo-Jimenez has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Dag Aarsland
Centre for Age‐related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway
11 shared publicationsFrancisco Lopera
Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia
7 shared publicationsMiguel Germán Borda
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway; Faculty of Health Sciences, University of Stavanger, Stavanger, Norway; Semillero de Neurociencias y Envejecimiento, Ageing Institute, Medical School, Pontificia Universidad Javeriana, Bogotá, Colombia
7 shared publications- Diego Alejandro Tovar-Rios
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway
6 shared publications - Dag Aarsland
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway
5 shared publications - David Aguillon
Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
5 shared publications
Latest Publications
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e103714
Mega‐Analysis of Oscillatory and Aperiodic Resting‐State EEG Alterations in Neurodegenerative Diseases
Background: Resting‐state EEG (rsEEG) alterations in the posterior alpha rhythm are promising biomarkers of neurodegenerative diseases (NDDs). However, spectral analysis often overlooks the rsEEG non‐rhythmic (aperiodic) component. Studies assessing the oscillatory and aperiodic activity are scarce and frequently underpowered. While multicenter data pooling (mega‐analysis) can enhance statistical power, it may introduce site‐related differences (batch effects). This mega‐analysis differentiates rsEEG oscillatory and aperiodic alterations across NDDs while mitigating batch effects. Method: RsEEGs from 1750 subjects across 12 sites were preprocessed. We pooled signals from healthy controls (HC = 583), Parkinson's Disease (PD = 131), Lewy Body Dementias (LBD = 96), Alzheimer's Disease (AD = 403), Frontotemporal Dementia (FTD = 36), Mild Cognitive Impairment (MCI) in Lewy Bodies pathology or PD (MCI‐LBD = 34), MCI in AD spectrum (MCI‐AD = 245), and Vascular Dementia (VD = 222); Figure 1A. Batch effects harmonization of the posterior power spectrum was performed with reComBat (age and diagnosis‐adjusted). We evaluated harmonization through functional and mass‐univariate permutation ANOVAs. Oscillatory and aperiodic parameters were extracted from the harmonized spectrum with specparam. Group differences across NDDs were estimated with bootstrap pairwise comparisons, mass‐univariate permutation tests, and logistic regression models (age‐adjusted). Result: Visualizations and statistical testing supported reduced batch effects after harmonization; Figure 1B and 1C. As consistent results in the unharmonized and harmonized data, steeper aperiodic parameters and lower oscillatory center frequency characterized LBD compared to all other groups. Besides, oscillatory extended alpha power was lower in AD than in HC and PD; Figure 2. Harmonized oscillatory center frequency and aperiodic parameters improved the separation of LBD compared to unharmonized parameters; Figure 3. Conclusion: Harmonization mitigates batch effects in the rsEEG posterior power spectrum. LBD is characterized by pronounced oscillatory frequency slowing and increased aperiodic activity, while AD displays both oscillatory and aperiodic abnormalities with smaller effect sizes.
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e103714
Open AccessMega‐Analysis of Oscillatory and Aperiodic Resting‐State EEG Alterations in Neurodegenerative Diseases
Background: Resting‐state EEG (rsEEG) alterations in the posterior alpha rhythm are promising biomarkers of neurodegenerative diseases (NDDs). However, spectral analysis often overlooks the rsEEG non‐rhythmic (aperiodic) component. Studies assessing the oscillatory and aperiodic activity are scarce and frequently underpowered. While multicenter data pooling (mega‐analysis) can enhance statistical power, it may introduce site‐related differences (batch effects). This mega‐analysis differentiates rsEEG oscillatory and aperiodic alterations across NDDs while mitigating batch effects. Method: RsEEGs from 1750 subjects across 12 sites were preprocessed. We pooled signals from healthy controls (HC = 583), Parkinson's Disease (PD = 131), Lewy Body Dementias (LBD = 96), Alzheimer's Disease (AD = 403), Frontotemporal Dementia (FTD = 36), Mild Cognitive Impairment (MCI) in Lewy Bodies pathology or PD (MCI‐LBD = 34), MCI in AD spectrum (MCI‐AD = 245), and Vascular Dementia (VD = 222); Figure 1A. Batch effects harmonization of the posterior power spectrum was performed with reComBat (age and diagnosis‐adjusted). We evaluated harmonization through functional and mass‐univariate permutation ANOVAs. Oscillatory and aperiodic parameters were extracted from the harmonized spectrum with specparam. Group differences across NDDs were estimated with bootstrap pairwise comparisons, mass‐univariate permutation tests, and logistic regression models (age‐adjusted). Result: Visualizations and statistical testing supported reduced batch effects after harmonization; Figure 1B and 1C. As consistent results in the unharmonized and harmonized data, steeper aperiodic parameters and lower oscillatory center frequency characterized LBD compared to all other groups. Besides, oscillatory extended alpha power was lower in AD than in HC and PD; Figure 2. Harmonized oscillatory center frequency and aperiodic parameters improved the separation of LBD compared to unharmonized parameters; Figure 3. Conclusion: Harmonization mitigates batch effects in the rsEEG posterior power spectrum. LBD is characterized by pronounced oscillatory frequency slowing and increased aperiodic activity, while AD displays both oscillatory and aperiodic abnormalities with smaller effect sizes.
- Open Access
- 17 September 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 197 (Pt B) , 111080
Characterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study
- 17 September 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 197 (Pt B) , 111080
Open AccessCharacterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study
- Open Access
- 2 July 2025
- Published by Elsevier in Clinical Neurophysiology Practice
- Vol. 10, 222-233
Quantitative electroencephalography in the diagnosis of dementia with Lewy bodies
- 2 July 2025
- Published by Elsevier in Clinical Neurophysiology Practice
- Vol. 10, 222-233
Open AccessQuantitative electroencephalography in the diagnosis of dementia with Lewy bodies
- Open Access
Characterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study
Background Abnormalities in resting-state electroencephalogram (rsEEG) posterior alpha rhythm are promising biomarkers of neurodegenerative diseases (NDDs), often assessed via spectral analysis, ignoring the signal’s non-rhythmic (aperiodic) component. Evidence assessing aperiodic and oscillatory rsEEG abnormalities across NDDs is scarce and often underpowered. Multicenter studies could tackle these limitations, but data pooling might introduce site-related rsEEG differences (batch effects). This study aims to characterize rsEEG oscillatory and aperiodic patterns across NDDs, minimizing potential batch effects. Methods RsEEGs (n = 639; 11 sites) were automatically preprocessed. Signals comprised healthy controls (HC = 153), Lewy Body Dementias (LBD = 95), Parkinson’s Disease (PD = 71), Alzheimer’s Disease (AD = 186), Frontotemporal Dementia (FTD = 23), Mild Cognitive Impairment (MCI) in positive Lewy Body pathology or PD (MCI-LBD = 34), and MCI in positive AD pathology (MCI-AD = 77). Power spectrum batch effects were harmonized using reComBat (age, sex, and diagnosis-adjusted). Harmonization was evaluated with functional and mass-univariate ANOVAs. Oscillatory and aperiodic parameters were extracted from the batch-harmonized power spectrum. NDDs-related differences were estimated with functional and mass-univariate tests, bootstrapped pairwise comparisons, and logistic regressions. Results Qualitative visualizations and statistical testing showed reduced batch effects after harmonization. Statistically significant findings included steeper aperiodic parameters and lower oscillatory center frequency in LBD compared to other NDDs. Additionally, oscillatory extended alpha power was lower in AD vs. LBD. Conclusions Batch effects in the rsEEG power spectrum can be mitigated with harmonization. Oscillatory alpha power reduction may better reflect AD abnormalities, whereas pronounced oscillatory frequency slowing and greater aperiodic activity characterize LBD.
Open AccessCharacterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study
Background Abnormalities in resting-state electroencephalogram (rsEEG) posterior alpha rhythm are promising biomarkers of neurodegenerative diseases (NDDs), often assessed via spectral analysis, ignoring the signal’s non-rhythmic (aperiodic) component. Evidence assessing aperiodic and oscillatory rsEEG abnormalities across NDDs is scarce and often underpowered. Multicenter studies could tackle these limitations, but data pooling might introduce site-related rsEEG differences (batch effects). This study aims to characterize rsEEG oscillatory and aperiodic patterns across NDDs, minimizing potential batch effects. Methods RsEEGs (n = 639; 11 sites) were automatically preprocessed. Signals comprised healthy controls (HC = 153), Lewy Body Dementias (LBD = 95), Parkinson’s Disease (PD = 71), Alzheimer’s Disease (AD = 186), Frontotemporal Dementia (FTD = 23), Mild Cognitive Impairment (MCI) in positive Lewy Body pathology or PD (MCI-LBD = 34), and MCI in positive AD pathology (MCI-AD = 77). Power spectrum batch effects were harmonized using reComBat (age, sex, and diagnosis-adjusted). Harmonization was evaluated with functional and mass-univariate ANOVAs. Oscillatory and aperiodic parameters were extracted from the batch-harmonized power spectrum. NDDs-related differences were estimated with functional and mass-univariate tests, bootstrapped pairwise comparisons, and logistic regressions. Results Qualitative visualizations and statistical testing showed reduced batch effects after harmonization. Statistically significant findings included steeper aperiodic parameters and lower oscillatory center frequency in LBD compared to other NDDs. Additionally, oscillatory extended alpha power was lower in AD vs. LBD. Conclusions Batch effects in the rsEEG power spectrum can be mitigated with harmonization. Oscillatory alpha power reduction may better reflect AD abnormalities, whereas pronounced oscillatory frequency slowing and greater aperiodic activity characterize LBD.
- Open Access
- 24 September 2024
- Published by Elsevier in Clinical Neurophysiology
- Vol. 167, 241-253
ComBat models for harmonization of resting-state EEG features in multisite studies
- 24 September 2024
- Published by Elsevier in Clinical Neurophysiology
- Vol. 167, 241-253
Open AccessComBat models for harmonization of resting-state EEG features in multisite studies
- Open Access
- 8 May 2024
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (3) , 885-906
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians
This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and prodromal Alzheimer’s disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, and indications for disease management. The core clinical features of dementia with Lewy bodies (DLB)—parkinsonism, complex visual hallucinations, cognitive fluctuations, and REM sleep behaviour disorder are common prodromal symptoms. Supportive clinical features of pDLB include severe neuroleptic sensitivity, as well as autonomic and neuropsychiatric symptoms. The neuropsychological profile in mild cognitive impairment attributable to Lewy body pathology (MCI-LB) tends to include impairment in visuospatial skills and executive functioning, distinguishing it from MCI due to AD, which typically presents with impairment in memory. pDLB may present with cognitive impairment, psychiatric symptoms, and/or recurrent episodes of delirium, indicating that it is not necessarily synonymous with MCI-LB. Imaging, fluid and other biomarkers may play a crucial role in differentiating pDLB from pAD. The current MCI-LB criteria recognise low dopamine transporter uptake using positron emission tomography or single photon emission computed tomography (SPECT), loss of REM atonia on polysomnography, and sympathetic cardiac denervation using meta-iodobenzylguanidine SPECT as indicative biomarkers with slowing of dominant frequency on EEG among others as supportive biomarkers. This review also highlights the emergence of fluid and skin-based biomarkers. There is little research evidence for the treatment of pDLB, but pharmacological and non-pharmacological treatments for DLB may be discussed with patients. Non-pharmacological interventions such as diet, exercise, and cognitive stimulation may provide benefit, while evaluation and management of contributing factors like medications and sleep disturbances are vital. There is a need to expand research across diverse patient populations to address existing disparities in clinical trial participation. In conclusion, an early and accurate diagnosis of pDLB or pAD presents an opportunity for tailored interventions, improved healthcare outcomes, and enhanced quality of life for patients and care partners.
- 8 May 2024
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (3) , 885-906
Open AccessDifferentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians
This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and prodromal Alzheimer’s disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, and indications for disease management. The core clinical features of dementia with Lewy bodies (DLB)—parkinsonism, complex visual hallucinations, cognitive fluctuations, and REM sleep behaviour disorder are common prodromal symptoms. Supportive clinical features of pDLB include severe neuroleptic sensitivity, as well as autonomic and neuropsychiatric symptoms. The neuropsychological profile in mild cognitive impairment attributable to Lewy body pathology (MCI-LB) tends to include impairment in visuospatial skills and executive functioning, distinguishing it from MCI due to AD, which typically presents with impairment in memory. pDLB may present with cognitive impairment, psychiatric symptoms, and/or recurrent episodes of delirium, indicating that it is not necessarily synonymous with MCI-LB. Imaging, fluid and other biomarkers may play a crucial role in differentiating pDLB from pAD. The current MCI-LB criteria recognise low dopamine transporter uptake using positron emission tomography or single photon emission computed tomography (SPECT), loss of REM atonia on polysomnography, and sympathetic cardiac denervation using meta-iodobenzylguanidine SPECT as indicative biomarkers with slowing of dominant frequency on EEG among others as supportive biomarkers. This review also highlights the emergence of fluid and skin-based biomarkers. There is little research evidence for the treatment of pDLB, but pharmacological and non-pharmacological treatments for DLB may be discussed with patients. Non-pharmacological interventions such as diet, exercise, and cognitive stimulation may provide benefit, while evaluation and management of contributing factors like medications and sleep disturbances are vital. There is a need to expand research across diverse patient populations to address existing disparities in clinical trial participation. In conclusion, an early and accurate diagnosis of pDLB or pAD presents an opportunity for tailored interventions, improved healthcare outcomes, and enhanced quality of life for patients and care partners.
- 7 December 2023
- Published by Elsevier in Revista Colombiana de Psiquiatria (english Ed.)
- Vol. 52 (4) , 305-313
Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment
- 7 December 2023
- Published by Elsevier in Revista Colombiana de Psiquiatria (english Ed.)
- Vol. 52 (4) , 305-313
Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment
- 1 October 2023
- Published by Elsevier in Revista Colombiana de Psiquiatría
- Vol. 52 (4) , 305-313
Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment
- 1 October 2023
- Published by Elsevier in Revista Colombiana de Psiquiatría
- Vol. 52 (4) , 305-313
Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment
- 10 May 2023
- Published by Elsevier in Mitochondrion
- Vol. 71, 17-25
Serum TCA cycle metabolites in Lewy bodies dementia and Alzheimer's disease: Network analysis and cognitive prognosis
- 10 May 2023
- Published by Elsevier in Mitochondrion
- Vol. 71, 17-25
Serum TCA cycle metabolites in Lewy bodies dementia and Alzheimer's disease: Network analysis and cognitive prognosis
- Open Access
- 24 April 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 151, 28-40
Spectral features of resting-state EEG in Parkinson's Disease: A multicenter study using functional data analysis
- 24 April 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 151, 28-40
Open AccessSpectral features of resting-state EEG in Parkinson's Disease: A multicenter study using functional data analysis